Home・Список акций・Cerus Corp

Cerus Corp

Закрыт

СекторЗдравоохранение

2.29 2.23

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.12

Макс.

2.29

Ключевые показатели
By Trading Economics
Доход	-1.3M -3M
Продажи	-2.5M 57M
Прибыль на акцию	-0.01
Рентабельность продаж	-5.191
Сотрудники	261
EBITDA	-1.5M -712K

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+128.31% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-182M 433M
Предыдущая цена открытия	0.06
Предыдущая цена закрытия	2.29

Новостные настроения

By Acuity

50%

175 / 340 Рейтинг в Healthcare

Cerus Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:11 UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

3 авг. 2026 г., 19:56 UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

31 июл. 2026 г., 23:06 UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

30 июл. 2026 г., 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

29 июл. 2026 г., 19:56 UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

28 июл. 2026 г., 16:02 UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

27 июл. 2026 г., 20:07 UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

24 июл. 2026 г., 19:06 UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

23 июл. 2026 г., 09:01 UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

22 июл. 2026 г., 15:46 UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

21 июл. 2026 г., 21:41 UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Сравнение c конкурентами

Изменение цены

Cerus Corp Прогноз

Целевая цена

By TipRanks

128.31% рост

Прогноз на 12 месяцев

Средняя 5 USD 128.31%

Максимум 5 USD

Минимум 5 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Cerus Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям Cerus Corp – Данные за последние 3 месяца.

Настроения

By Acuity

175 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.